Kenneth M Attie

This inventor holds 8 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Acceleron Pharma Inc., Celgene Corporation. Active years: 2017-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenneth M Attie. Retrieved from https://idiyas.com/inventor/kenneth-m-attie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 1.5

ph-index = 4

Forward Citations = 68(Granted Patents)

Company Filing History:

8 out of 172

Acceleron Pharma Inc.

where one patent can have more than one assignee

Years Active: 2017-2022

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11524990 - Methods for treating vascular eye disorders with ActRII antagonists (2022-12-13),

2. 11471510 - Activin-ActRII antagonists and uses for treating anemia (2022-10-18),

3. 11260107 - Methods and compositions for treating ulcers (2022-03-01),

4. 10829531 - Methods for treating myelodysplastic syndromes and sideroblastic anemias (2020-11-10),

5. 10550170 - Methods for treating vascular eye disorders with actrii antagonists (2020-02-04),

6. 10487144 - Methods for treating ulcers in a hemoglobinopathy anemia with a soluble actRIIB polypeptide (2019-11-26),

7. 10189882 - Methods for treating myelodysplastic syndromes and sideroblastic anemias (2019-01-29),

8. 9850298 - Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptide (2017-12-26),

Title: The Innovative Contributions of Kenneth M Attie

Introduction

Kenneth M Attie is a prominent inventor based in Boston, MA, known for his significant contributions to the field of medical science. With a total of 8 patents to his name, Attie's work primarily focuses on innovative methods for treating various health conditions, particularly those related to eye disorders and anemia.

Latest Patents

Among his latest patents, Attie has developed methods for treating vascular eye disorders using ActRII antagonists. These compositions and methods aim to enhance visual acuity in patients and address vascular disorders of the eye. Additionally, he has created methods for treating anemia, specifically targeting conditions that require red blood cell transfusions and other related syndromes. His work involves the administration of Activin-ActRII signaling inhibitors to effectively treat these conditions in mammals.

Career Highlights

Throughout his career, Kenneth M Attie has worked with notable companies such as Acceleron Pharma Inc. and Celgene Corporation. His experience in these organizations has allowed him to advance his research and contribute to the development of groundbreaking medical treatments.

Collaborations

Attie has collaborated with esteemed colleagues, including Christopher Robert Rovaldi and Matthew L Sherman, further enhancing the impact of his work in the medical field.

Conclusion

Kenneth M Attie's innovative contributions to medical science, particularly in the treatment of vascular eye disorders and anemia, highlight his role as a leading inventor. His patents and collaborations reflect a commitment to improving patient care and advancing medical research.

Profile summary based on public USPTO records.